Marktanalyse - Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017

Global Markets Direct
02.2017
94 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) — Pipeline Review, H1 2017, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 16 and 2 respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development

AbbVie Inc

Amarantus Bioscience Holdings Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Coronis NeuroSciences Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

H. Lundbeck A/S

Intra-Cellular Therapies Inc

Iproteos SL

Luc Therapeutics Inc

Neuralstem Inc

Pfizer Inc

Sage Therapeutics Inc

Saniona AB

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Sunovion Pharmaceuticals Inc

Takeda Pharmaceutical Company Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles

A-431404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQW-051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-5736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basmisanil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

davunetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-3748 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltoprazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPR-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITI-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUAF-64280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-03463275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04958242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roflumilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGE-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKLA-4R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-14040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-831 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones

Featured News & Press Releases

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a 'RETOS-Colaboración” grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2017 (Contd..1), H1 2017

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus